Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 7/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344739 | 0.84 | LMNA (0.55) | HRH3LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL6339003 | 0.84 | MAPT (0.52) | HRH3LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL6337034 | 0.84 | HRH3 (0.46) | HRH3LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL6337027 | 0.76 | ACACB (0.50) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6338939 | 0.75 | OPRM1 (0.40) | LIPEOPRM1OPRD1OPRK1 | |
| SCHEMBL1092092 | 0.74 | MAPT (0.62) | — | |
| SCHEMBL13194647 | 0.74 | MAPT (0.47) | — | |
| SCHEMBL1390119 | 0.73 | NNMT (0.60) | LMNA | |
| SCHEMBL1092214 | 0.72 | MAPT (0.48) | — | |
| SCHEMBL21628757 | 0.72 | ALDH1A1 (0.48) | HRH3LMNAOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890932-B2 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1101755-B1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6649656-B1 | Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents | TEIJIN LIMITED (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1101755-A1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | IGLV6-57, FCGRT, IGSF11 | HRH3 2245/4885LMNA 4233/4885MLNR 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.